ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $192.80.

ICUI has been the topic of a number of recent analyst reports. KeyCorp raised their price target on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a research note on Friday, August 7th. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Piper Sandler boosted their target price on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Needham & Company LLC upped their target price on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th.

ICU Medical Trading Down 0.2%

NASDAQ ICUI opened at $155.62 on Thursday. The stock has a market capitalization of $3.89 billion, a P/E ratio of 131.88, a P/E/G ratio of 1.97 and a beta of 0.75. The business has a 50 day simple moving average of $168.40 and a 200 day simple moving average of $145.25. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. ICU Medical has a one year low of $112.50 and a one year high of $192.85.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same quarter in the prior year, the business earned $2.10 earnings per share. The business’s quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Research analysts expect that ICU Medical will post 7.19 earnings per share for the current year.

Insider Transactions at ICU Medical

In related news, VP Daniel Woolson sold 5,417 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the transaction, the vice president owned 17,062 shares in the company, valued at approximately $3,093,852.46. This represents a 24.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elisha Finney sold 378 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the transaction, the director directly owned 4,871 shares in the company, valued at $888,860.08. This represents a 7.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 21,830 shares of company stock valued at $3,905,003. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in ICU Medical in the second quarter valued at $3,744,000. Allworth Financial LP lifted its stake in ICU Medical by 155.1% during the second quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 107 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of ICU Medical by 1.7% in the 2nd quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier’s stock worth $960,000 after purchasing an additional 109 shares in the last quarter. Nykredit A S purchased a new position in shares of ICU Medical in the 2nd quarter worth about $135,000. Finally, Amundi increased its position in shares of ICU Medical by 31.5% during the 2nd quarter. Amundi now owns 8,512 shares of the medical instruments supplier’s stock valued at $1,248,000 after purchasing an additional 2,037 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices used in infusion therapy, critical care and oncology. Its product portfolio includes infusion pumps, IV administration sets, needle-free connectors, vascular access devices, patient monitoring equipment and related accessories designed to support the delivery of fluids and medications and the monitoring of patients in healthcare settings.

The company also provides products for the safe handling of hazardous drugs, including closed-system transfer devices used in oncology and pharmacy operations.